JeanChristophe Tellier - UCB SA Chairman of the Executive Committee, CEO
| UCB Stock | EUR 185.90 0.40 0.22% |
Chairman
Mr. JeanChristophe Tellier has served as Chairman of the Executive Committee, Chief Executive Officer, Executive Director of UCB S.A. since January 1, 2015. Before that, he was Member of the Executive Committee, Executive Vice President and President of European Operations of the Company from July 1, 2011. He joined the Company from Ipsen where he was President General Manager Ipsen US. His role at Ipsen was to strengthen Ipsen specialty care business in North America, in the areas of endocrinology and neurology. He joined Ipsen in May 2009. He started his career in 1988 in the marketing department of Synthelabo and joined Ciba France as Group Marketing Manager in 1990 and got various marketing sales position until leading the Marketing Sales department. In 1997, following the merger of Ciba and Sandoz to form Novartis, he was appointed Head of the Mass Market Business unit in France until the end of 1999 where he became Chief Operating Officer of Novartis France. From 2003 to mid2006, JC Tellier was Chief Executive Officer of Novartis Pharma Belgium and during his tenure was elected president of Pharma.be, the Pharma trade association. At the end of 2006, he was promoted to Head of the Global Arthritis, Bone and Muscle disease Business Franchise at Novartis Headquarters in Basel, Switzerland. In February 2007, he was appointed Chairman and CEO of Novartis Pharma France and Novartis Group France until mid 2008 when he decided to join MacroGenics Inc., a Marylandbased biotechnology company, as Executive Vice President and Chief Commercial Officer. He is physician specialized in rheumatology and followed diverse executive training both at INSEAD and Harvard. since 2015.
| Age | 64 |
| Tenure | 9 years |
| Phone | 32 2 559 99 99 |
| Web | https://www.ucb.com |
UCB SA Management Efficiency
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| Charles Beauduin | Barco NV | 64 | |
| Jurgen Tinggren | NV Bekaert SA | N/A | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 |
UCB SA Leadership Team
Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sandrine CFA, Ex CFO | ||
| Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head | ||
| William Silbey, Exec Counsel | ||
| Pr LowFriedrich, Chief VP | ||
| Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | ||
| Kirsten LundJurgensen, Ex Solutions | ||
| Caroline Vancoillie, Chief Functions | ||
| JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee | ||
| JeanChristophe Tellier, Chairman of the Executive Committee, CEO |
UCB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 15.81 B | |||
| Shares Outstanding | 189.96 M | |||
| Shares Owned By Insiders | 38.03 % | |||
| Shares Owned By Institutions | 40.78 % | |||
| Price To Earning | 17.19 X | |||
| Price To Book | 1.55 X |
Pair Trading with UCB SA
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if UCB SA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UCB SA will appreciate offsetting losses from the drop in the long position's value.Moving against UCB Stock
| 0.8 | IMMO | Immobel | PairCorr |
| 0.79 | ATEB | Atenor SA | PairCorr |
| 0.74 | BPOST | Bpost NV | PairCorr |
| 0.72 | GREEN | Greenyard NV | PairCorr |
| 0.61 | CENER | Cenergy Holdings | PairCorr |
The ability to find closely correlated positions to UCB SA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace UCB SA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back UCB SA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling UCB SA to buy it.
The correlation of UCB SA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as UCB SA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if UCB SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for UCB SA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for UCB Stock Analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.